WO2013133031A1 - ジペプチジルペプチダーゼ-iv阻害剤 - Google Patents
ジペプチジルペプチダーゼ-iv阻害剤 Download PDFInfo
- Publication number
- WO2013133031A1 WO2013133031A1 PCT/JP2013/054291 JP2013054291W WO2013133031A1 WO 2013133031 A1 WO2013133031 A1 WO 2013133031A1 JP 2013054291 W JP2013054291 W JP 2013054291W WO 2013133031 A1 WO2013133031 A1 WO 2013133031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- val
- pro
- amino acid
- inhibitor
- Prior art date
Links
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title claims abstract description 29
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title claims abstract description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 110
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 84
- 230000002792 vascular Effects 0.000 claims abstract description 40
- 230000007935 neutral effect Effects 0.000 claims abstract description 36
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims abstract description 29
- 239000003112 inhibitor Substances 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 claims abstract description 14
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 13
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 13
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims abstract description 11
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims abstract description 11
- 125000003368 amide group Chemical group 0.000 claims abstract description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004471 Glycine Substances 0.000 claims abstract description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000004279 alanine Nutrition 0.000 claims abstract description 3
- 235000009582 asparagine Nutrition 0.000 claims abstract description 3
- 229960001230 asparagine Drugs 0.000 claims abstract description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000004554 glutamine Nutrition 0.000 claims abstract description 3
- 229930182817 methionine Natural products 0.000 claims abstract description 3
- 235000006109 methionine Nutrition 0.000 claims abstract description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004474 valine Substances 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 81
- 230000002401 inhibitory effect Effects 0.000 claims description 71
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 60
- 201000010099 disease Diseases 0.000 claims description 55
- 235000013305 food Nutrition 0.000 claims description 44
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 41
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 41
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 41
- 230000003511 endothelial effect Effects 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 28
- 206010012601 diabetes mellitus Diseases 0.000 claims description 28
- 239000008103 glucose Substances 0.000 claims description 28
- 206010020772 Hypertension Diseases 0.000 claims description 27
- 230000005764 inhibitory process Effects 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 230000006872 improvement Effects 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 208000019553 vascular disease Diseases 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 10
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- XBJKAZATRJBDCU-GUBZILKMSA-N Val-Pro-Ala Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O XBJKAZATRJBDCU-GUBZILKMSA-N 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 7
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 6
- GQMNEJMFMCJJTD-NHCYSSNCSA-N Val-Pro-Gln Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O GQMNEJMFMCJJTD-NHCYSSNCSA-N 0.000 claims description 5
- 108010064997 VPY tripeptide Proteins 0.000 claims description 4
- LGXUZJIQCGXKGZ-QXEWZRGKSA-N Val-Pro-Asn Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)O)N LGXUZJIQCGXKGZ-QXEWZRGKSA-N 0.000 claims description 4
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 claims description 4
- BGXVHVMJZCSOCA-AVGNSLFASA-N Val-Pro-Lys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N BGXVHVMJZCSOCA-AVGNSLFASA-N 0.000 claims description 4
- WANVRBAZGSICCP-SRVKXCTJSA-N Val-Pro-Met Chemical compound CSCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C)C(O)=O WANVRBAZGSICCP-SRVKXCTJSA-N 0.000 claims description 4
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 claims description 4
- QWCZXKIFPWPQHR-JYJNAYRXSA-N Val-Pro-Tyr Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QWCZXKIFPWPQHR-JYJNAYRXSA-N 0.000 claims description 4
- QSPOLEBZTMESFY-SRVKXCTJSA-N Val-Pro-Val Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O QSPOLEBZTMESFY-SRVKXCTJSA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 3
- 230000002641 glycemic effect Effects 0.000 claims 1
- 125000001151 peptidyl group Chemical group 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 abstract description 10
- -1 aliphatic amino acids Chemical class 0.000 abstract description 8
- 229940024606 amino acid Drugs 0.000 abstract description 8
- 235000001014 amino acid Nutrition 0.000 abstract description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 59
- 102000004190 Enzymes Human genes 0.000 description 32
- 229940088598 enzyme Drugs 0.000 description 32
- 108090000790 Enzymes Proteins 0.000 description 31
- 102000011632 Caseins Human genes 0.000 description 24
- 108010076119 Caseins Proteins 0.000 description 24
- 239000005018 casein Substances 0.000 description 24
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 24
- 235000021240 caseins Nutrition 0.000 description 24
- 201000001421 hyperglycemia Diseases 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 208000035475 disorder Diseases 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 230000009471 action Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 239000002220 antihypertensive agent Substances 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 11
- 239000004365 Protease Substances 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 102000004157 Hydrolases Human genes 0.000 description 9
- 108090000604 Hydrolases Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940030600 antihypertensive agent Drugs 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 238000006911 enzymatic reaction Methods 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000004278 EU approved seasoning Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229940125708 antidiabetic agent Drugs 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 235000011194 food seasoning agent Nutrition 0.000 description 6
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 6
- 239000000859 incretin Substances 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 230000001766 physiological effect Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 210000003556 vascular endothelial cell Anatomy 0.000 description 6
- 206010059245 Angiopathy Diseases 0.000 description 5
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 5
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 5
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 235000013611 frozen food Nutrition 0.000 description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 5
- 230000003301 hydrolyzing effect Effects 0.000 description 5
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 4
- 208000024248 Vascular System injury Diseases 0.000 description 4
- 208000012339 Vascular injury Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 101800004538 Bradykinin Proteins 0.000 description 3
- 102400000967 Bradykinin Human genes 0.000 description 3
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 101710180012 Protease 7 Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000009101 diabetic angiopathy Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 229960004279 formaldehyde Drugs 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000004810 partition chromatography Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000014493 regulation of gene expression Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 206010010164 Hypertension complications Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- IRVONVRHHJXWTK-RWMBFGLXSA-N Met-Lys-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N IRVONVRHHJXWTK-RWMBFGLXSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical class OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 235000014613 canned/preserved soup Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000006912 hydrolase reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000000864 hyperglycemic agent Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000014109 instant soup Nutrition 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 108010022588 methionyl-lysyl-proline Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a dipeptidyl peptidase-IV inhibitor and the like.
- Dipeptidyl peptidase-IV (di- peptidyl peptidase-IV: hereinafter also referred to as “DPP-4”) is a multifunctional transmembrane glycoprotein having N-terminal dipeptidase activity. It is present on most mammalian cells and is present in various tissues such as the liver, kidney, small intestine, salivary gland, blood cells and plasma, so it is assumed that it has a broad role in vivo and is created. It is an enzyme that has recently attracted attention as a drug target.
- Dipeptidyl peptidase-IV is known to be a degrading enzyme of glucagon-like peptide 1 (hereinafter referred to as “GLP-1”) and glucose-dependent insulinotropic polypeptide (hereinafter referred to as “GIP”) of incretin. ing.
- GLP-1 glucagon-like peptide 1
- GIP glucose-dependent insulinotropic polypeptide
- the dipeptidyl peptidase-IV inhibitor having an action of inhibiting dipeptidyl peptidase-IV activity is expected to be used as an antidiabetic agent.
- dipeptidyl peptidase-IV inhibitors are still a new genre of therapeutic agents compared to insulin secretion inhibitors and glucose absorption inhibitors, and many new substances having dipeptidyl peptidase-IV inhibitory activity can be found. It is desired.
- the first step in the treatment of diabetes is diet therapy and exercise therapy, and when the blood glucose level cannot be controlled even now, pharmaceuticals for treating diabetes are currently used. Therefore, if it is possible to provide a substance having dipeptidyl peptidase-IV inhibitory activity as a supplement or food additive, it is considered that it can contribute widely to the improvement of blood glucose level.
- Patent Document 1 discloses that a bicyclic pyrimidine is used as a dipeptidyl peptidase-IV inhibitor for treating or preventing diabetes.
- casein is subjected to alkaline decomposition by adjusting pH and temperature, and then various peptides such as proteases are further adjusted to separate and purify various peptides from hydrolyzed products.
- a dipeptidyl peptidase-IV inhibitory action has been found among them.
- dipeptidyl peptidase-IV inhibitors derived from food see, for example, Patent Documents 3 to 5).
- isolated peptides obtained by isolating only one peptide from casein or whey hydrolyzate are IPI, LPL, KVLP, LPVPQK, VPLGTQ, VPYPQ, PLLQ, GPFP, LPVPQ, LPQYL, MPLW, YVPEPF, PQSVLS, PFP, LPVP, EMPFPK, LPLP, GPFPIIV, APFPE, HPIK and AFPPEVF are described, and dipeptidyl peptidase-IV inhibition test results of these isolated peptides are disclosed.
- dipeptidyl peptidase-IV inhibitors have been disclosed in the past, for example, in Patent Document 1, an organic synthetic compound requires a complicated synthesis process, and future verification is necessary regarding safety. . Any dipeptidyl peptidase-IV inhibitor should be considered, and the current situation is that the search for dipeptidyl peptidase-IV inhibitors is not sufficient.
- search for novel peptides and various physiological activity of peptides have been conducted.
- the present invention is to provide an excellent dipeptidyl peptidase-IV inhibitor.
- peptide having a dipeptidyl peptidase-IV inhibitory action is contained in a casein hydrolyzate obtained by hydrolyzing casein with a specific enzyme. It has also been found that there are a plurality of them, and that there are novel peptides in them. From this result, the peptide was Val-Pro-X [wherein X represents an amino acid residue (excluding L-proline residue)] (SEQ ID NO: 1) (hereinafter referred to as “peptide”). The present invention was completed.
- this peptide is a food-derived component, it is considered to be highly safe, and this peptide VPX can also be provided as a supplement or food additive. Therefore, it is considered that the peptide VPX of the present disclosure can widely contribute to the improvement of blood glucose level.
- the peptide VPX of the present disclosure includes a peptide having an angiotensin converting enzyme inhibitory action, it is considered that the peptide VPX of the present disclosure can widely contribute to the improvement of hypertension. From the above, it can be said that the peptide VPX of the present disclosure is a more effective substance with added value.
- the present invention is a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)).
- a dipeptidyl peptidase-IV inhibitor and / or angiotensin converting enzyme comprising a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)) as an active ingredient
- a blood glucose level-inhibiting agent, hyperglycemia improving agent, antidiabetic comprising a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)) as an active ingredient
- X is a basic amino acid residue, an aliphatic neutral amino acid residue, a neutral amino acid residue having a hydroxy group, a neutral amino acid residue having an amide group, or a neutral amino acid residue having an aromatic group. Is preferred.
- Said X is preferably selected from alanine, glutamine, methionine, asparagine, glycine, valine, tyrosine, serine and lysine residues. .
- L-amino acids are also preferred. It is preferable that the peptide is selected from peptides consisting of any one of the following amino acid sequences (a) to (i).
- Val-Pro-Ala (VPA: SEQ ID NO: 2)
- B Val-Pro-Gln (VPQ: SEQ ID NO: 3)
- C Val-Pro-Met (VPM: SEQ ID NO: 4)
- D Val-Pro-Asn
- E Val-Pro-Gly
- VPG Val ID NO: 6
- F Val-Pro-Val
- VV SEQ ID NO: 7
- G Val-Pro-Tyr
- H Val-Pro-Ser
- VK Val-Pro-Lys
- the present invention can provide a dipeptidyl peptidase-IV inhibitor, a blood glucose level increase inhibitor, a vascular endothelial disorder inhibitor, and the like. .
- the peptide of the present disclosure has an amino acid sequence (SEQ ID NO: 1) represented by a peptide consisting of Val-Pro-X.
- Val (V) represents a valine residue
- Pro (P) represents a proline residue
- X represents any amino acid residue.
- These amino acid residues are preferably L-type.
- the X is not particularly limited, and examples thereof include amino acid residues that can be obtained from milk protein degradation products, and those selected from these amino acid residues are preferable.
- X is preferably 20 natural amino acids.
- the free amino acid is generally indicated by “ + H 3 N— (R 1 ) CH—COO ⁇ ”, and the peptide of the present disclosure is referred to as “Val-Pro-HN— (R 1 ) CH—COOH”. It is also possible to show.
- the amino acid residues represented by X can be classified into acidic amino acid residues, basic amino acid residues, and neutral amino acid residues. Said X can be selected from one or more of the following
- Examples of the acidic amino acid residue include an aspartic acid residue (Asp (D)) and a glutamic acid residue (Glu (E)). Of these, those having two carbonyl groups are preferred.
- Examples of the basic amino acid residue include a lysine residue (Lys (K)), an arginine residue (Arg (R)), a histidine residue (His (H)), and the like. Of these, those having 2 to 4 amino groups are preferred.
- neutral amino acid residues examples include those having R 1 of the amino acid residue X having hydrogen and an alkyl group; a hydroxy group; sulfur; an acid amide; an aromatic group, and the like. Aliphatic neutral amino acid residues; neutral amino acid residues having a hydroxy group; neutral amino acid residues having a sulfur; neutral amino acid residues having an amide group; neutral amino acid residues having an aromatic group is there.
- the neutral amino acid residues As the aliphatic neutral amino acid residues, alanine residues (Ala (A)), glycine residues (Gly (G)), valine residues (Val (V)), leucine residues (Leu (L)), An isoleucine residue (Ile (I)) and the like can be mentioned.
- the neutral amino acid residue which has hydrogen or an alkyl group whose R ⁇ 1 > of the said amino acid residue X is hydrogen or an alkyl group is preferable.
- the alkyl group is preferably a straight chain or branched chain, and more preferably a branched chain.
- the carbon number of R 1 in the aliphatic neutral amino acid residue is preferably 0-4, more preferably 0-3.
- R 1 hydrogen, methyl group (—CH 3 ) or isopropyl group (—CH (CH 3 ) 2 ).
- the neutral amino acid residue having a hydroxy group include a serine residue (Ser (S)) and a threonine residue (Thr (T)).
- R 1 of the amino acid residue X is preferably a C 1-2 alkyl group having a hydroxy group.
- the neutral amino acid residue having sulfur include a cysteine residue (Cys (C)) and a methionine residue (Met (M)).
- Examples of the neutral amino acid residue having the amide group include a glutamine residue (Gln (Q)) and an asparagine residue (Asn (N)).
- R 1 of the amino acid residue X is preferably an alkyl group having 1 to 2 carbon atoms having an amide group.
- the aromatic neutral amino acid residue include phenylalanine residue (Phe (F)), tyrosine residue (Tyr (Y)), tryptophan residue (Trp (W)) and the like.
- R 1 of the amino acid residue X is preferably a benzyl group (eg, HO—C 6 H 4 —CH 2 — or HC 6 H 4 —CH 2 — etc.) which may have a hydroxy group, The number of hydroxyl groups is preferably 0-1.
- amino acid residues described above basic amino acid residues and neutral amino acid residues are preferred.
- neutral amino acid residues an aliphatic neutral amino acid residue, a neutral amino acid residue having a hydroxy group, a neutral amino acid residue having an amide group, and a neutral amino acid residue having an aromatic group are preferred.
- an aliphatic neutral amino acid residue and a neutral amino acid residue having an amide group are preferred.
- amino acid residues represented by X those selected from alanine residue, glutamine residue, methionine residue, asparagine residue, glycine residue, valine residue, tyrosine residue, serine residue and lysine residue Is preferred.
- alanine residues, glutamine residues, asparagine residues, glycine residues, valine residues, tyrosine residues and serine residues are preferred.
- an alanine residue, a glutamine residue, and a valine residue are preferable in terms of physiological activity.
- dipeptidyl peptidase-IV inhibitory activity preferably an alanine residue, a glutamine residue, an asparagine residue, a glycine residue, a valine residue, a tyrosine residue, a serine residue and a lysine residue, and an angiotensin Alanine residue and lysine residue are particularly preferable in terms of converting enzyme inhibitory activity.
- Val-Pro-Ala (VPA: SEQ ID NO: 2) Val-Pro-Gln (VPQ: SEQ ID NO: 3), Val-Pro-Met (VPM: SEQ ID NO: 4), Val-Pro-Asn (VPN: SEQ ID NO: 5) Val-Pro-Gly (VPG: SEQ ID NO: 6), Val-Pro-Val (VPV: SEQ ID NO: 7), Val-Pro-Tyr (VPY: SEQ ID NO: 8), Val-Pro-Ser (VPS: SEQ ID NO: 9), and tripeptides such as Val-Pro-Lys (VPK: SEQ ID NO: 10).
- the peptide of the present disclosure may be a salt of this peptide.
- the salts include alkali metals such as potassium and sodium; alkaline earth metals such as calcium and magnesium, and one or more of them may be used as appropriate.
- the method for producing the peptide VPX of the present disclosure can be performed according to a method described in, for example, International Publication No. 2003/044044 Pamphlet [Reference 1], and the following methods are exemplified. This is not particularly limited.
- a protein or peptide containing the amino acid sequence represented by Val-Pro-X (SEQ ID NO: 1) or the amino acid sequence represented by SEQ ID NO: 2 to 10 is decomposed by hydrolysis, etc.
- a method obtained by separating and purifying a method obtained by synthesizing peptide VPX by a peptide chemical synthesis method, and then separating and purifying peptide VPX from the obtained synthesized product; a plant producing peptide VPX and a peptide containing the peptide VPX, Examples include extraction from animals and microorganisms, and separation and purification from the obtained extract.
- the peptide VPX of the present disclosure can be produced, for example, by appropriately hydrolyzing a protein such as casein with an acid alkali or an enzyme.
- a method for obtaining the peptide VPX by hydrolyzing a raw material protein with a hydrolase is exemplified. First, before hydrolyzing a raw material protein with an enzyme, the protein is dissolved, dispersed or suspended in water.
- the raw material protein is not particularly limited as long as it is a protein containing VPX and can produce the peptide of the present disclosure when appropriately digested with a hydrolase. Examples of the protein include those derived from animals and microorganisms, and casein that is available in large quantities is preferable.
- the treatment method varies depending on the properties of the raw protein, but if the raw protein is soluble, the raw protein may be dispersed and dissolved in water or warm water, and if it is poorly soluble, the protein will be dissolved in hot water. May be homogenized by mixing and stirring.
- an alkaline agent or an acid agent may be added to the protein-containing solution to adjust the pH appropriately (eg, pH 7 to 10).
- This pH is preferably adjusted to the optimum pH of the hydrolase used or in the vicinity thereof.
- the alkali agent include hydroxides such as sodium hydroxide and calcium hydroxide; carbonates such as potassium carbonate, and the like, and these may be alkali metal salts or alkaline earth metal salts.
- the acid agent include inorganic acids such as hydrochloric acid and phosphoric acid; organic acids such as citric acid, acetic acid, and formic acid. Of these, one or more may be used as appropriate.
- a predetermined amount of hydrolase is added to the solution containing the protein and reacted at a temperature of about 10 to 85 ° C. for 0.1 to 48 hours to obtain a hydrolyzate.
- the solution is maintained at an appropriate temperature according to the type of the enzyme, for example, 30 to 60 ° C., preferably 45 to 55 ° C. to start protein hydrolysis. Is desirable.
- the hydrolysis reaction time may be continued until the desired decomposition rate is reached while monitoring the decomposition rate of the enzyme reaction.
- the degradation rate of the starting protein is preferably 20 to 55% in order to obtain the peptide of the present disclosure.
- the hydrolase reaction is stopped, for example, by deactivation of the enzyme in the hydrolyzate, and can be performed by a heat deactivation treatment by a conventional method.
- the heating temperature and holding time of the heat deactivation treatment can be appropriately set in consideration of the thermal stability of the enzyme used, and can be set as appropriate under conditions that can be sufficiently deactivated, for example, at a temperature range of 80 to 130 ° C. for 30 minutes. It can be performed with a holding time of ⁇ 2 seconds.
- the hydrolase is not particularly limited, but is preferably an enzyme that can hydrolyze the raw protein to produce the peptide of the present disclosure.
- the enzyme that can be produced is preferably an endopeptidase.
- endopeptidase examples include those derived from microorganisms and animals. Specific examples include proteases derived from bacteria belonging to the genus Bacillus and Aspergillus, and proteases derived from animal pancreas. A commercially available protease can be used. Preferable examples of commercially available proteases include proteases derived from Aspergillus bacteria such as protease A (manufactured by Amano Enzyme); and proteases derived from animal pancreas such as pancreatin (manufactured by Amano Enzyme).
- a protease derived from Aspergillus when used, it is desirable to add it at a rate of 100 to 5000 active units per gram of protein.
- a protease derived from animal pancreas when using a protease derived from animal pancreas, it is desirable to add it at a rate of 3000 to 8000 active units per gram of protein.
- peptide VPX of the present disclosure It is preferable to isolate or purify the peptide VPX of the present disclosure from the hydrolyzate.
- Purification of the peptide VPX of the present disclosure is usually performed in the same manner as used for purification of oligopeptides, such as ion exchange chromatography, adsorption chromatography, reverse phase chromatography, partition chromatography, gel filtration chromatography and the like. It can be carried out by appropriately combining methods such as various types of chromatography, solvent precipitation, salting out, and partitioning between the two liquid phases.
- the fraction containing the target substance can be determined using the dipeptidyl peptidase-IV inhibitory action and / or the angiotensin converting enzyme inhibitory action described below as an index. Moreover, the active ingredient of those fractions can be identified by mass spectrometry.
- the proteolytic product obtained by hydrolase preferably contains at least VPX, and is more preferably an active ingredient prepared so as to contain the amino acid sequence represented by SEQ ID NOs: 2 to 10. It is preferable in that it can be easily recovered.
- the peptide VPX of this indication can be manufactured also by chemical synthesis.
- the chemical synthesis of the peptide VPX of the present disclosure can be performed by a liquid phase method or a solid phase method which is usually used for the synthesis of oligopeptides.
- the synthesized peptide is deprotected as necessary, and unreacted reagents and by-products can be removed to isolate the peptide VPX of the present disclosure.
- Such peptide synthesis can be performed using a commercially available peptide synthesizer.
- the fact that the target peptide was obtained can be confirmed using the dipeptidyl peptidase-IV inhibitory action and / or the angiotensin converting enzyme inhibitory action described below as indicators.
- the peptide VPX of the present disclosure has a dipeptidyl peptidase-IV inhibitory action, as shown in Examples below.
- Dipeptidyl peptidase-IV may cause various diseases and symptoms by decomposing compounds involved in physiological functions in vivo. For this reason, inhibition of dipeptidyl peptidase-IV takes advantage of dipeptidyl peptidase-IV by utilizing the fact that the life span of compounds involved in physiological functions in vivo that have been degraded by dipeptidyl peptidase-IV is extended. Prevention, amelioration, or treatment of the disease or symptom that occurs.
- Examples of the compound involved in the physiological function include glucagon-like peptide 1 (GLP-1) of incretin and glucose-dependent insulinotropic polypeptide (GIP). And by inhibiting the degradation of glucagon-like peptide 1 of this incretin, glucose-induced stimulation of insulin biosynthesis and secretion, glucagon secretion inhibition, regulation of gene expression, nutritional effects on sputum cells, suppression of food intake, In addition, it is possible to achieve various actions such as slowing of gastric emptying. This can contribute to normalization of the elevated blood glucose level and improvement / adjustment of hunger and body weight.
- GLP-1 glucose-dependent insulinotropic polypeptide
- dipeptidyl peptidase-IV reduces the function of vascular endothelial cells and damages vascular endothelial cells.
- This decrease in blood vessel endothelial function or damage causes vascular disorders such as vasoconstriction, arteriosclerosis, and thrombus formation due to increased vascular tension, and these causes cause organ blood flow disorders, organ dysfunction, and diabetes. Complications will be induced.
- dipeptidyl peptidase-IV inhibitors for example, see References 2 to 5 [Reference 2] Endocrine Journal 2011, 58 (1), 69-73. [Reference 3] J Am Coll Cardiol.
- dipeptidyl peptidase-IV inhibitors In order to break this vicious circle, a combination of dipeptidyl peptidase-IV inhibitors and angiotensin converting enzyme inhibitors has been tried, and dipeptidyl peptidase-IV inhibitors also play an important role in the treatment of cardiovascular system It is considered a thing.
- the peptide VPX of the present disclosure has a dipeptidyl peptidase-IV inhibitory action, it suppresses blood sugar levels, suppresses hyperglycemia, suppresses vascular endothelial function, suppresses vascular endothelial disorders, suppresses vascular disorders, It shows an endothelial cell protective effect and an appetite suppressing effect.
- the peptide VPX of the present disclosure is capable of suppressing appetite and protecting vascular endothelial cells.
- “suppressing the increase in blood glucose level” here means including a decrease in blood glucose level, and particularly means “being able to lower a blood glucose level that is higher than a normal value or higher than necessary”.
- the determination of the normal value of the blood glucose level may be based on the 2010 diagnostic criteria of the Japan Diabetes Society. Furthermore, by inhibiting dipeptidyl peptidase-IV with the peptide VPX of the present disclosure, it is considered possible to prevent, improve, or treat diseases and symptoms caused by dipeptidyl peptidase-IV. Therefore, the peptide VPX of the present disclosure can be used in a method for preventing, ameliorating and / or treating diseases and symptoms caused by dipeptidyl peptidase-IV after ingestion or administration to animals including humans. it can.
- Examples of various diseases and symptoms caused by dipeptidyl peptidase-IV of the present disclosure include hyperglycemia, diabetes, diabetic complications, vascular endothelial disorder, and vascular disorder.
- the various diseases caused by dipeptidyl peptidase-IV may be various diseases mediated by dipeptidyl peptidase-IV.
- various diseases caused by hyperglycemia, diabetes and hyperglycemia conditions include, for example, diabetic microangiopathy (eg retinopathy, nephropathy, neuropathy, etc.) and macrovascular complications (eg angina) Ischemic heart disease such as symptom / myocardial infarction, cerebral infarction, obstructive arteriosclerosis, gangrene, etc.).
- the dipeptidyl peptidase-IV inhibitor can be used as a prophylactic or therapeutic agent for the above-mentioned various diseases is as disclosed in the aforementioned Patent Documents 1 to 5 and Reference Documents 2 to 5. It goes without saying that the disclosed peptide VPX can also be implemented as a prophylactic or therapeutic agent for the various diseases. Therefore, the peptide VPX of the present disclosure may be used for dipeptidyl peptidase-IV inhibition, suppression of increase in blood glucose level, improvement of hyperglycemia, suppression of vascular endothelial damage, anti-diabetes, etc.
- angiotensin converting enzyme (hereinafter also referred to as “ACE”) inhibitory action as shown in Examples below.
- the angiotensin converting enzyme is an enzyme that acts on angiotensin I generated from angiotensinogen by cleavage with renin, liberates two C-terminal amino acids, and converts them into angiotensin II.
- Angiotensin converting enzyme generates angiotensin II having a strong pressor action and also has an action of inactivating bradykinin having a hypotensive action.
- Inhibiting angiotensin-converting enzyme in addition to blood pressure lowering action and bradykinin inactivating action, cardiac hypertrophy retraction action, peripheral vasodilation action, renal protection action, substance P degradation inhibition action, etc. are possible, and depending on the hypertension state It is considered that an inhibitory action on vascular endothelial injury, an inhibitory action on vascular injury, and the like are possible. It is also known that an angiotensin converting enzyme inhibitor is effective in improving essential hypertension. Further, by inhibiting angiotensin converting enzyme, it is considered possible to prevent, improve or treat diseases and symptoms caused by angiotensin converting enzyme.
- diseases and symptoms caused by angiotensin converting enzyme include hypertension, cardiac hypertrophy, and renal hypertrophy.
- the various diseases caused by angiotensin converting enzyme may be various diseases mediated by angiotensin converting enzyme.
- diseases and symptoms caused by hypertension or hypertension include cardiovascular diseases and vascular disorders such as cerebral hemorrhage, cerebral infarction, angina pectoris, myocardial infarction, renal failure, visual impairment, and angioedema. .
- the peptide VPX of the present disclosure has an angiotensin converting enzyme inhibitory action, the blood pressure lowering action, the bradykinin inactivating action, the hypertensive symptom improving action, the vascular endothelial disorder inhibiting action caused by the hypertension state, and the vascular disorder inhibiting action The action etc. are shown. Furthermore, by inhibiting the angiotensin converting enzyme with the peptide VPX of the present disclosure, it is considered possible to prevent, ameliorate, or treat diseases and symptoms caused by the above-mentioned angiotensin converting enzyme.
- the peptide VPX of the present disclosure can be used in a method for preventing, ameliorating and / or treating a disease or symptom caused by an angiotensin converting enzyme by ingestion or administration to an animal including a human.
- an angiotensin converting enzyme inhibitor can be used as a prophylactic or therapeutic agent for the above-mentioned various diseases is as disclosed in Patent Documents 1 and 6 to 8, and the peptide VPX of the present disclosure is also disclosed.
- the present invention can also be implemented as a prophylactic or therapeutic agent for the various diseases.
- the peptide VPX of the present disclosure may be used for angiotensin converting enzyme inhibition, blood pressure lowering, hypertension and the like, and uses as described above for angiotensin converting enzyme inhibitor, blood pressure lowering agent, antihypertensive agent and the like.
- the peptide VPX of the present disclosure can be provided as a more useful compound when it has two effects of suppressing blood glucose level increase and lowering blood pressure.
- the function of the endothelial cells of the blood vessels decreases and vascular endothelial damage is likely to occur, but high blood pressure that gives a strong load to the blood vessels increases the risk of causing vascular damage.
- Factors (NO and PGI2) that relax vascular smooth muscle are produced from vascular endothelial cells.
- NO and PGI2 that relax vascular smooth muscle are produced from vascular endothelial cells.
- their releasing ability also decreases.
- diabetics have high blood pressure.
- high blood pressure falls into a vicious circle that places a load on vascular endothelial cells.
- a person who is diabetic or a spare group thereof needs to pay attention to hypertension.
- the spare group is a person who has not yet been diabetic but has a high blood glucose level
- blood pressure can be lowered even if the blood sugar level is lowered with a hyperglycemic drug
- blood sugar can be lowered even if the blood pressure is lowered with a blood pressure lowering drug.
- diabetic and hypertensive humans are often prescribed both hyperglycemia-improving drugs and antihypertensive drugs, and there is a concern of side effects due to the combination of drugs. By having such an effect, it is possible to reduce the amount of drug used, and therefore, side effects can be expected to be reduced.
- the peptide VPX of the present disclosure can be said to be very effective for improving blood vessels, suppressing vascular endothelial damage and preventing, improving or treating diabetes, and particularly for preventing, improving or treating vascular endothelial damage caused by hyperglycemic conditions. It is considered effective.
- Specific diseases and symptoms of the vascular endothelial disorder of the present disclosure include, for example, diabetic vascular disorder.
- the peptide VPX of the present disclosure and the above-mentioned various preparations containing this as an active ingredient are ingested or administered to animals including humans, Prevention, improvement and improvement of hyperglycemia, diabetes (especially type 2 diabetes), hypertension and diabetic complications (for example, diabetic vascular endothelial disorder, nephropathy, hypertension, etc.), vascular endothelial disorder, vascular disorder, etc. And / or can be used in methods for treatment.
- the above-mentioned various preparations containing the peptide VPX of the present disclosure as an active ingredient are ingested or administered to animals including humans, and the above-mentioned hyperglycemia, diabetes (especially type 2 diabetes) and diabetic complications (for example, , Diabetic vascular endothelial disorder, nephropathy, hypertension, etc.), vascular endothelial disorder, vascular disorder and the like can be used in a method for preventing, improving and / or treating.
- the peptide VPX of the present disclosure and the above-mentioned various preparations containing the peptide VPX as an active ingredient are humans for the prevention, improvement and / or treatment of hyperglycemia, diabetes, vascular disorders, hypertension and the like as described above. It can be blended and used as an active ingredient of animal drugs, quasi drugs, skin preparations, cosmetics, foods and the like. When blended in a pharmaceutical product, it can be an oral or parenteral agent. In addition, when blended in foods, various diseases caused by the above-mentioned dipeptidyl peptidase-IV and / or various diseases caused by angiotensin converting enzyme, and various diseases caused by hyperglycemia and / or hypertension, etc.
- peptide VPX of the present disclosure and the above-mentioned various preparations containing this as an active ingredient are human or animal for the prevention, amelioration and / or treatment of hyperglycemia, diabetes, hypertension, vascular disorders and the like as described above.
- the peptide VPX of the present disclosure and the above-described various preparations containing the peptide VPX as an active ingredient may be either oral administration or parenteral administration, but oral administration is desirable.
- Parenteral administration includes intravenous injection, rectal administration, inhalation and the like.
- Examples of the dosage form for oral administration include tablets, capsules, troches, syrups, granules, acid agents, ointments and the like.
- components such as excipients, pH adjusters, coloring agents, and corrigents that are commonly used for formulation can be used.
- the peptide VPX of the present disclosure is contained in a food as an active ingredient, and as one aspect of the above-described various preparations containing the peptide VPX of the present disclosure and the active ingredient, dipeptidyl peptidase-IV action and / or angiotensin conversion It can also be processed as a food having an enzyme inhibitory action.
- examples of such foods include liquids, pastes, solids, powders, etc.
- liquid foods, feeds (including for pets), etc. for example, flour products, instant foods, processed agricultural products, Processed marine products, processed livestock products, milk / dairy products, fats and oils, basic seasonings, compound seasonings / foods, frozen foods, beverages, and other commercial products.
- examples of the flour product include bread, macaroni, spaghetti, noodles, cake mix, fried flour, bread crumbs and the like.
- examples of the instant foods include instant noodles, cup noodles, retort / cooked food, cooking canned food, microwave food, instant soup / stew, instant miso soup / soup, canned soup, freeze-dried food, and other instant foods.
- examples of the processed agricultural products include canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products, cereals (cereal processed products), and the like.
- examples of the processed fishery products include canned fishery products, fish hams and sausages, fish paste products, marine delicacies, and tsukudani.
- Examples of the processed livestock products include canned livestock, pastes, livestock ham, sausages and the like.
- Examples of the milk / dairy products include processed milk, milk beverages, yogurts, lactic acid bacteria beverages, cheese, ice creams, prepared powdered milks, creams, and other dairy products.
- Examples of the fats and oils include butter, margarines, and vegetable oils.
- the basic seasonings include soy sauce, miso, sauces, tomato processed seasonings, mirins, vinegars, etc.
- the combined seasonings and foods include cooking mixes, curry ingredients, sauces, Examples include dressings, noodle soups, spices, and other complex seasonings.
- Examples of the frozen food include raw material frozen food, semi-cooked frozen food, cooked frozen food, and the like.
- the confectionery examples include caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pie, snacks, crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery, and other confectionery.
- the beverages include carbonated beverages, natural fruit juices, fruit juice beverages, soft drinks with fruit juices, fruit drinks, fruit drinks with fruits, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks Sports drinks, nutritional drinks, alcoholic drinks, other taste drinks, and the like.
- examples of commercially available foods other than the above include baby foods, sprinkles, and tea paste.
- the compounding amount of the peptide VPX of the present disclosure is preferably at least 0.001% by mass with respect to the final composition of the preparation.
- the dose of the peptide VPX of the present disclosure varies depending on age, symptoms, etc., but is usually 0.001 to 3000 mg / day, preferably 0.01 to 30 mg / day, and is divided into 1 to 3 times a day. It may be administered.
- Production Example 1 Production of VPX Peptide by Enzymatic Degradation of Casein ⁇ 1> Enzymatic Degradation of Casein 900 g of water was added to 100 g of commercially available casein (manufactured by New Zealand Daily Board), dispersed well, and sodium hydroxide was added to adjust the pH of the solution. Was adjusted to 7.0 to completely dissolve casein. The aqueous casein solution was sterilized by heating at 85 ° C.
- HPLC condition 1 Column: Cadenza CD-C18 10 mmI. D. ⁇ 250mm (manufactured by Intact Corporation) Detection: UV 215nm Flow rate: 3 ml / min Eluent A: Aqueous solution containing 0.2% FA Eluent B: Acetonitrile solution containing 0.2% FA From 98% of Eluent A, 75% after 30 minutes, 50% after 40 minutes
- the hydrolyzate was separated under a gradient condition of 20% after 43 minutes, and the eluate was fractionated every 0.75 ml.
- the ⁇ 1> casein hydrolyzate has dipeptidyl peptidase-IV inhibitory activity, and in the degraded product, VPV (SEQ ID NO: 7), VPY (SEQ ID NO: 8), VPK (SEQ ID NO: 10) ) was also confirmed. All of these amino acid residues were L-type.
- VPQ SEQ ID NO: 3
- a spectrum similar to that in the purified fraction (molecular weight (M) by mass spectrometry: 342.2) was obtained.
- VPM SEQ ID NO: 4
- VPN SEQ ID NO: 5
- VPG SEQ ID NO: 6
- VPV SEQ ID NO: 7
- VPY SEQ ID NO: 8
- VPS SEQ ID NO: 9
- VPK VPK
- Test Example 1 Dipeptidyl peptidase-IV inhibitory activity confirmation test of each peptide The dipeptidyl peptidase-IV inhibitory activity confirmation test of each peptide obtained in Production Example 2 shown in Table 1 was conducted, and the results are shown in Table 1. .
- Test Example 2 Angiotensin converting enzyme inhibitory activity confirmation test of each peptide
- VPA SEQ ID NO: 2
- VPK VPK
- the 50% inhibitory concentration was 24.8 ⁇ g, respectively. / Ml and 132 ⁇ g / ml. Therefore, since this VPA and VPK have both dipeptidyl peptidase-IV inhibitory activity and angiotensin converting enzyme inhibitory activity, they are very effective for vascular improvement, vascular endothelial disorder suppression and diabetes prevention, improvement or treatment. It can be said.
- the enzyme degradation product of casein containing at least one of these tripeptides (SEQ ID NOs: 2 to 10) is used as a material or food having a dipeptidyl peptidase-IV inhibitory action, an angiotensin converting enzyme inhibitory action, etc. I think it can be used for food, medicine, etc.
- VPA was found in the casein degradation products of CU5000 (manufactured by Morinaga Milk Industry Co., Ltd.), and the 50% inhibitory concentration of these dipeptidyl peptidase-IV inhibitors was 84 ⁇ g / ml. Met.
- the 50% inhibitory concentration of dipeptidyl peptidase-IV inhibition for C800 is> 1000 ⁇ g / ml, and dipeptidyl peptidase-IV inhibitory activity is not observed even in casein degradation products. was there.
- DPP-4 dipeptidyl peptidase-IV inhibitory activity
- the measurement of dipeptidyl peptidase-IV (DPP-4) inhibition was performed according to the method of Kato et al. “Kato, T. et al. Biochem. Med. 19, p351, 1978”. Specifically, the enzyme reaction was performed using Recombinant Human DPPIV / CD26 (R & D Systems, Inc.) as the enzyme (DPP-4) and H-Gly-Pro-AMC (Biomol GmbH) as the substrate.
- Inhibition rate (%) 100% ⁇ [(Yb) / (Xa)] ⁇ 100%
- X water + enzyme + substrate
- Y test substance + enzyme + substrate a: water + substrate b: test substance + substrate
- IC 50 was calculated by calculating back the concentration at which the inhibition rate of the enzyme was 50%.
- ACE inhibition angiotensin converting enzyme inhibition
- the peptide VPX of the present invention can be isolated from casein hydrolyzate, it is highly safe and can be used in a wide range of fields such as pharmaceuticals, foods, topical skin preparations and functional foods. It is.
- a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)).
- Val-Pro-Ala SEQ ID NO: 2
- B Val-Pro-Gln
- C Val-Pro-Met
- D Val-Pro-Asn
- E Val-Pro-Gly
- F Val-Pro-Val
- G Val-Pro-Tyr
- H Val-Pro-Ser
- I Val-Pro-Lys (SEQ ID NO: 10)
- VPA SEQ ID NO: 2
- VPQ SEQ ID NO: 3
- VPN SEQ ID NO: 5
- VPG SEQ ID NO: 6
- VPV SEQ ID NO: 7
- VPY SEQ ID NO: 8
- VPS SEQ ID NO: 9
- VPK VPK
- VPA SEQ ID NO: 2
- VPQ SEQ ID NO: 3
- VPV SEQ ID NO: 7
- VPA angiotensin converting enzyme inhibitory activity
- VPA SEQ ID NO: 2
- VPK SEQ ID NO: 10
- One or more peptides consisting of Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)), or any one of the above-mentioned [2] to [4] Containing the peptide according to item as an active ingredient, A dipeptidyl peptidase-IV inhibitor, a hyperglycemia improving agent, a blood glucose level increase inhibitor, an antidiabetic agent, a vascular endothelial disorder inhibitor, a blood vessel improving agent, an angiotensin converting enzyme inhibitor, an antihypertensive agent or an antihypertensive agent.
- Dipeptidyl peptidase-IV inhibitor for the manufacture of Use of a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)) or the peptide according to any one of [2] to [4] above.
- a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)), or a peptide according to any one of [2] to [4] above of, Use for dipeptidyl peptidase-IV inhibitor, hyperglycemia improving agent, blood glucose level increasing inhibitor, antidiabetic agent, vascular endothelial disorder inhibitor, vascular improving agent, angiotensin converting enzyme inhibitor, antihypertensive agent or antihypertensive agent .
- a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)), or a peptide according to any one of [2] to [4] above of, Use for dipeptidyl peptidase-IV-inhibiting foods, foods for lowering blood sugar, foods for anti-diabetes, foods for suppressing vascular endothelial injury or foods for improving blood vessels.
- a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)) or a peptide according to any one of [2] to [4] above.
- a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)), or a peptide according to any one of [2] to [4] above
- X represents an amino acid residue (excluding L-proline residue)
- a treatment method Prevention and improvement of diseases caused by dipeptidyl peptidase-IV, diseases caused by hyperglycemic conditions, diabetes, diseases caused by vascular endothelial or vascular disorders, diseases caused by angiotensin converting enzyme, diseases caused by hypertension Or a treatment method.
- a peptide comprising Val-Pro-X (wherein X represents an amino acid residue (excluding L-proline residue)) or a peptide according to any one of [2] to [4] above.
- the disease and / or symptom caused by the dipeptidyl peptidase-IV is preferably selected from hyperglycemia, diabetes, diabetic complications, vascular endothelial disorder and vascular disorder.
- the disease and / or symptom caused by the angiotensin converting enzyme is selected from hypertension and cardiovascular disease.
- a peptide comprising Val-Pro-X obtained by hydrolyzing casein (wherein X represents an amino acid residue (excluding L-proline residue)), or the above-mentioned [2] to [4] The peptide of any one of these, and its manufacturing method.
- the peptide according to any one of [4] to [4] and a method for producing the peptide.
- A Performing with a hydrolase (preferably endopeptidase). It is preferably carried out under conditions of 10 to 85 ° C. and 0.1 to 48 hours.
- B Separating and purifying the hydrolyzate by chromatography.
- one or two kinds selected from ion exchange chromatography, reverse phase chromatography, partition chromatography and the like are used.
Abstract
Description
また、例えば、特許文献2には、カゼインを、pH及び温度を調整してアルカリ分解した後、さらにプロテアーゼ等の各種酵素を調整して酵素加水分解した加水分解物から、種々のペプチドを分離精製し、さらにその中からジペプチジルペプチダーゼ-IV阻害作用のあるものを見出したことが開示されている。その他にも食品由来のジペプチジルペプチダーゼ-IV阻害物質についての開示がある(例えば、特許文献3~5参照)。
また、例えば、特許文献6の表2には、カゼイン又はホエイ加水分解物から1つのペプチドだけを単離した単離ペプチドである、IPI、LPL、KVLP、LPVPQK、VPLGTQ、VPYPQ、PLLQ、GPFP、LPVPQ、LPQYL、MPLW、YVPEPF、PQSVLS、PFP、LPVP、EMPFPK、LPLP、GPFPIIV、APFPE、HPIK及びAPFPEVFが記載され、これら単離ペプチドのジペプチジルペプチダーゼ-IV阻害試験結果が開示されている。
また、ペプチドは有益な生理活性作用を有する場合があることから、新規ペプチドの探索及びペプチドの様々な生理活性作用の探求が行われている。しかし、ペプチド中のアミノ酸が増減したりアミノ酸の一部が異なると生理活性作用が低下若しくは消失することがあり、また、カゼイン等の乳由来の蛋白質の加水分解物中であっても無数のペプチドが混在するため、目的とする生理活性作用を有する新規又は既知のペプチドを見出すことは困難である。
よって、本発明は、優れたジペプチジルペプチダーゼ-IV阻害剤を提供することにある。
以上のことから、本開示のペプチドVPXは、より付加価値のある有効な物質と言える。
また、Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕を有効成分として含有するジペプチジルペプチダーゼ-IV阻害剤及び/又はアンジオテンシン変換酵素阻害剤である。
また、Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕を有効成分として含有する血糖値上昇抑制剤、高血糖改善剤、抗糖尿病剤、血圧降下剤、抗高血圧剤又は血管内皮障害抑制剤である。
前記Xは、塩基性アミノ酸残基、脂肪族中性アミノ酸残基、ヒドロキシ基を有する中性アミノ酸残基、アミド基を有する中性アミノ酸残基又は芳香族を有する中性アミノ酸残基であるのが好適である。
前記Xは、アラニン残基、グルタミン残基、メチオニン残基、アスパラギン残基、グリシン残基、バリン残基、チロシン残基、セリン残基及びリシン残基から選ばれるものであるのが好適である。また、L-アミノ酸が好適である。
前記ペプチドが、下記の(a)~(i)のいずれかのアミノ酸配列からなるペプチドから選ばれるものであるのが、好適である。
(a)Val-Pro-Ala(VPA:配列番号2)
(b)Val-Pro-Gln(VPQ:配列番号3)
(c)Val-Pro-Met(VPM:配列番号4)
(d)Val-Pro-Asn(VPN:配列番号5)
(e)Val-Pro-Gly(VPG:配列番号6)
(f)Val-Pro-Val(VPV:配列番号7)
(g)Val-Pro-Tyr(VPY:配列番号8)
(h)Val-Pro-Ser(VPS:配列番号9)
(i)Val-Pro-Lys(VPK:配列番号10)
本開示において、Val(V)はバリン残基、Pro(P)はプロリン残基、Xは任意のアミノ酸残基を示す。これらアミノ酸残基はL型であるのが好ましい。
前記Xは、特に限定されないが、例えば、乳蛋白質分解物から得ることができるアミノ酸残基を挙げることができ、これらアミノ酸残基から選ばれるものが好ましい。また、前記Xは、20種の天然アミノ酸が好ましい。なお、遊離アミノ酸は、一般的に「+H3N-(R1)CH-COO-」で示され、本開示のペプチドは、「Val-Pro-HN-(R1)CH-COOH」と示すことも可能である。
前記Xで示されるアミノ酸残基は、酸性アミノ酸残基、塩基性アミノ酸残基、中性アミノ酸残基に分類することが可能である。前記Xは、以下のアミノ酸残基の例示から1種又は2種以上選択することが可能である。
前記塩基性アミノ酸残基として、例えば、リシン残基(Lys(K))、アルギニン残基(Arg(R))、ヒスチジン残基(His(H))等が挙げられる。このうち、好ましくはアミノ基を2~4つもつものである。
前記ヒドロキシ基を有する中性アミノ酸残基として、セリン残基(Ser(S))、トレオニン残基(Thr(T))等が挙げられる。前記アミノ酸残基XのR1が、ヒドロキシ基を有する炭素数1~2のアルキル基が好ましい。
前記硫黄を有する中性アミノ酸残基として、システイン残基(Cys(C))及びメチオニン残基(Met(M))等が挙げられる。
前記アミド基を有する中性アミノ酸残基として、グルタミン残基(Gln(Q))、アスパラギン残基(Asn(N))等が挙げられる。このうち、好ましくはアミノ基を2つもつものである。また、前記アミノ酸残基XのR1がアミド基を有する炭素数1~2のアルキル基が好ましい。
前記芳香族を有する中性アミノ酸残基として、フェニルアラニン残基(Phe(F))、チロシン残基(Tyr(Y))、トリプトファン残基(Trp(W))等が挙げられる。前記アミノ酸残基XのR1は、ヒドロキシ基を有していてもよいベンジル基(例えば、HO-C6H4-CH2-又はH-C6H4-CH2-等)が好ましく、この水酸基の数は0~1が好ましい。
前記Xで示されるアミノ酸残基のうち、アラニン残基、グルタミン残基、メチオニン残基、アスパラギン残基、グリシン残基、バリン残基、チロシン残基、セリン残基及びリシン残基から選ばれるものが好適である。このうち、アラニン残基、グルタミン残基、アスパラギン残基、グリシン残基、バリン残基、チロシン残基及びセリン残基が好ましい。さらに、生理活性の点で、アラニン残基、グルタミン残基及びバリン残基が好ましい。
ジペプチジルペプチダーゼ-IV阻害活性の点で、好ましくは、アラニン残基、グルタミン残基、アスパラギン残基、グリシン残基、バリン残基、チロシン残基、セリン残基及びリシン残基であり、またアンジオテンシン変換酵素阻害活性の点で特に好ましくは、アラニン残基及びリシン残基である。
Val-Pro-Ala(VPA:配列番号2)Val-Pro-Gln(VPQ:配列番号3)、Val-Pro-Met(VPM:配列番号4)、Val-Pro-Asn(VPN:配列番号5)、Val-Pro-Gly(VPG:配列番号6)、Val-Pro-Val(VPV:配列番号7)、Val-Pro-Tyr(VPY:配列番号8)、Val-Pro-Ser(VPS:配列番号9)、Val-Pro-Lys(VPK:配列番号10)等のトリペプチドが挙げられる。
例えば、Val-Pro-X(配列番号1)で表されるアミノ酸配列又は配列番号2~10で表されるアミノ酸配列を含む蛋白質やペプチドを加水分解等にて分解し、得られた分解物から分離精製して得る方法;ペプチドの化学合成方法にてペプチドVPXを合成した後、得られた合成物からペプチドVPXを分離精製して得る方法;ペプチドVPX及びこれを含むペプチド等を生産する植物、動物や微生物から抽出し、得られた抽出物から分離精製する方法等が挙げられる。
原料蛋白質を加水分解酵素で加水分解して前記ペプチドVPXを得る方法を例示する。
まず、原料蛋白質を酵素で加水分解する前に、蛋白質を水に溶解、分散又は懸濁させる。
前記原料蛋白質は、VPXを含む蛋白質であって、適宜加水分解酵素で消化したときに本開示のペプチドが生成可能なものであれば、特に限定されない。前記蛋白質として、例えば、動物由来や微生物由来のもの等が挙げられ、大量に入手可能なカゼインが好適である。
このとき、原料蛋白質の性状により処法は異なるが、原料蛋白質が可溶性の場合には、原料蛋白質を水又は温水に分散し、溶解すればよく、また、難溶性の場合には熱水に蛋白質を混合撹拌にてホモジナイズすればよい。
前記アルカリ剤又は酸剤として、特に限定されず、食品又は医薬品に許容されるものを使用すればよい。アルカリ剤として、例えば、水酸化ナトリウムや水酸化カルシウム等の水酸化物;炭酸カリウム等の炭酸塩などが挙げられ、これらはアルカリ金属塩やアルカリ土類金属塩でもよい。また、酸剤として、例えば、塩酸、リン酸等の無機酸;クエン酸、酢酸、ギ酸等の有機酸などが挙げられる。これらのうち、適宜1種又は2種以上を使用すればよい。
また、前記蛋白質を含有する溶液を70~90℃で15秒~10分間程度加熱殺菌することが、雑菌汚染による変敗防止の点から望ましい。
このとき、前記加水分解酵素を添加した後、当該溶液を、酵素の種類に応じて適当な温度、例えば30~60℃、望ましくは45~55℃に保持して、蛋白質の加水分解を開始するのが望ましい。
また、加水分解反応時間は、酵素反応の分解率をモニターしながら、好ましい分解率に達するまで反応を続ければよい。前記原料蛋白質の分解率は20~55%が、本開示のペプチドを得るためには、望ましい。
前記加水分解酵素反応の停止は、例えば、加水分解液中の酵素の失活により行われ、常法による加熱失活処理により実施することができる。加熱失活処理の加熱温度と保持時間は、使用した酵素の熱安定性を考慮し、十分に失活できる条件を適宜設定することができるが、例えば、80~130℃の温度範囲で30分間~2秒間の保持時間で行うことができる。
例えば、アスペルギルス属細菌由来のプロテアーゼを使用する際には、蛋白質1g当たり100~5000活性単位の割合で添加するのが望ましい。また、動物膵臓由来のプロテアーゼを使用する際には、蛋白質1g当たり3000~8000活性単位の割合で添加するのが望ましい。
本開示において用いる加水分解酵素は、単独で又は2種以上組み合わせて使用してもよい。2種以上の酵素を用いる場合には、それぞれの酵素反応は同時に又は別々に行ってもよい。
本開示において、パンクレアチン及びプロテアーゼを併用するのが好ましく、これら2酵素を混合して使用することが特に好ましい。
分解率(%)=(ホルモール態窒素量/全窒素量)×100
本開示のペプチドVPXの精製は、通常、オリゴペプチドの精製に用いられているのと同様の手法、例えばイオン交換クロマトグラフィー、吸着クロマトグラフィー、逆相クロマトグラフィー、分配クロマトグラフィー、ゲル濾過クロマトグラフィー等の各種クロマトグラフィー、溶媒沈殿、塩析、2種の液相間での分配等の方法を適宜組み合わせることによって、行うことができる。
本開示のペプチドVPXの化学合成は、オリゴペプチドの合成に通常用いられている液相法または固相法によって行うことができる。合成されたペプチドは必要に応じて脱保護され、未反応試薬や副生物等を除去して、本開示のペプチドVPXを単離することが可能である。
このようなペプチドの合成は、市販のペプチド合成装置を用いて行うことができる。目的とするペプチドが得られたことは、後述するジペプチジルペプチダーゼ-IV阻害作用及び/又はアンジオテンシン変換酵素阻害作用を指標として確認することができる。
ジペプチジルペプチダーゼ-IVが、生体内の生理機能に関与している化合物を分解することで、種々の疾患や症状が生じる場合がある。このため、ジペプチジルペプチダーゼ-IVを阻害すると、ジペプチジルペプチダーゼ-IVによって分解されていた生体内の生理機能に関与している化合物の寿命が延びることを利用して、ジペプチジルペプチダーゼ-IVに起因する疾患や症状の予防、改善又は治療が可能となる。
前記生理機能に関与する化合物として、例えば、インクレチンのグルカゴン様ペプチド1(GLP-1)及びグルコース依存性インスリン分泌刺激ポリペプチド(GIP)が挙げられる。そして、このインクレチンのグルカゴン様ペプチド1の分解抑制によって、インスリンの生合成及び分泌に対するグルコース誘導性の刺激、グルカゴン分泌抑制、遺伝子発現の調整、Β細胞に対する栄養性の効果、食物摂取の抑制、及び胃内容排出の緩徐化などの各作用を奏することが可能である。
これによって、上昇した血糖値の正常化、並びに空腹感及び体重の改善・調整に寄与することが可能である。
近年、ジペプチジルペプチダーゼ-IV阻害薬の投与による内皮細胞の機能改善効果が多数報告されている(例えば、参考文献2~5参照〔参考文献2〕Endocrine Journal 2011, 58 (1), 69-73;〔参考文献3〕J Am Coll Cardiol. 2012, 59(3), 265-76;〔参考文献4〕Diabetes Care. 2011, 34(9), 2072-7;〔参考文献5〕Cardiovascular Diabetology 2011, 10(85) (http://www.cardiab.com/content/10/1/85))。
これらの効果は単に血糖値を下げることによる改善の他に、インクレチンによる血管の保護作用を介していると考えられている。高血糖により内皮細胞の機能が低下し、血管のしなやかさが失われると、血圧が上昇し、上昇した血圧がさらに血管を傷めるという悪循環が、心臓・腎臓・脳といった臓器への悪影響となって現れる。この悪循環を断ち切るために、ジペプチジルペプチダーゼ-IV阻害薬とアンジオテンシン変換酵素阻害薬の併用も試みられており、ジペプチジルペプチダーゼ-IVの阻害剤は循環器系の治療においても、重要な役割を果たすものと考えられている。
さらに、本開示のペプチドVPXにより、ジペプチジルペプチダーゼ-IVを阻害することで、ジペプチジルペプチダーゼ-IVに起因する疾患や症状の予防、改善又は治療が可能と考えられる。よって、本開示のペプチドVPXは、ヒトを含む動物に摂取又は投与して、ジペプチジルペプチダーゼ-IVに起因する疾患や症状等の予防、改善及び/又は治療を図るための方法に使用することができる。
本開示のジペプチジルペプチダーゼ-IVに起因する各種疾患や症状として、例えば、高血糖症、糖尿病、糖尿病合併症、血管内皮障害、血管障害等が挙げられる。なお、ジペプチジルペプチダーゼ-IVに起因する各種疾患等は、ジペプチジルペプチダーゼ-IVが介在する各種疾患等であってもよい。
さらに、高血糖症、糖尿病及び高血糖状態によって引き起こされる種々の疾患として、例えば、糖尿病性の細小血管症(例えば、網膜症、腎症、神経障害等)及び大血管合併症(例えば、狭心症・心筋梗塞等の虚血性心疾患、脳梗塞、閉塞性動脈硬化、壊疽等)等が挙げられる。
よって、本開示のペプチドVPXは、上述のような、ジペプチジルペプチダーゼ-IV阻害、血糖値上昇抑制、高血糖改善、血管内皮障害抑制、及び抗糖尿病等のために使用してもよく、また、ジペプチジルペプチダーゼ-IV阻害剤、血糖値上昇抑制剤、血管内皮障害抑制剤及び抗糖尿病剤等の上述のような使用を目的とした各種製剤に使用することができ、これら各種製剤を製造するために使用することができる。
ここで、アンジオテンシン変換酵素は、レニンによる切断によりアンジオテンシノーゲンから生じるアンジオテンシンIに働き、C末端の2個のアミノ酸を遊離させて、アンジオテンシンIIに変換する酵素である。
アンジオテンシン変換酵素は強い昇圧作用を有するアンジオテンシンIIを生成させるとともに、降圧作用を有するブラジキニンを不活性化する作用も有している。このため、既にアンジオテンシン変換酵素阻害剤は高血圧の治療薬として使用されており、カプトプリル及びレニベースなどが医薬品に使用されている。しかしながら、副作用として、カプトプリル及びレニベースでは過度の降圧作用や腎機能障害が見られることがある。このようなことから、サプリメントや食品添加物として提供しても安全性が高いものが望まれ、アンジオテンシン変換酵素阻害作用を有する物質の探索が多数報告されている(参考文献1、6~8参照。〔参考文献1〕国際公開2003/044044号パンフレット;〔参考文献6〕特開平6-40944号号公報;〔特許文献7〕特開2001-136995号号公報:〔参考文献8〕特開平7-101982号公報)。
例えば、参考文献6及び7には、カゼイン等を乳酸菌又はプロテイナーゼとペプチダーゼの組み合わせにより分解して得たVal-Pro-ProとIle-Pro-Proにアンジオテンシン変換酵素阻害作用があることが知られている。この他、アンジオテンシン変換酵素阻害作用を有するトリペプチドとして、例えば、参考文献8にはLeu-Leu-Trpが知られ、また参考文献1にはMet-Lys-Proが知られている。
さらに、アンジオテンシン変換酵素を阻害することで、アンジオテンシン変換酵素に起因する疾患や症状予防、改善又は治療が可能と考えられる。
アンジオテンシン変換酵素に起因する疾患や症状として、例えば、高血圧症、心臓肥大、腎臓肥大等が挙げられる。なお、アンジオテンシン変換酵素に起因する各種疾患等は、アンジオテンシン変換酵素が介在する各種疾患等であってもよい。
また、高血圧症又は高血圧状態によって引き起こされる種々の疾患や症状は、例えば、脳出血、脳梗塞、狭心症、心筋梗塞、腎不全、視力障害、血管浮腫等の心血管疾患や血管障害が挙げられる。
なお、アンジオテンシン変換酵素阻害剤が前記種々の疾患の予防剤や治療剤として利用できることについては、前記の特許文献1及び6~8にも開示されているとおりであり、本開示のペプチドVPXについても同様に前記種々の疾患の予防剤や治療剤としても実施できることについては言うまでもない。
よって、本開示のペプチドVPXは、アンジオテンシン変換酵素阻害、血圧降下及び高血圧症等のために使用してもよく、またアンジオテンシン変換酵素阻害剤、血圧降下剤及び抗高血圧剤等の上述のような使用を目的とした各種製剤に使用することができ、これら各種製剤を製造するために使用することができる。
ところで、高血糖値状態が続くと、血管の内皮細胞の機能が低下し、血管内皮障害が生じやすいが、さらにその血管に強い負荷を与えるような高血圧は血管障害を引き起こす危険性を高めることで知られている。血管内皮細胞からは、血管平滑筋を弛緩させる因子(NOやPGI2)が産生されている。そして、高血糖により血管内皮細胞の機能が低下するとそれらの遊離能力も低下する。結果として、糖尿病患者は高血圧を併発する。さらに、高い血圧が血管内皮細胞に負荷をかける悪循環に陥る。
このような効能を併せ持つことにより、薬剤の使用量も減らすことが可能となるので、副作用の低減が期待できる。
本開示の血管内皮障害の具体的な疾患及び症状として、例えば、糖尿病性の血管障害などが挙げられる。
また、本開示のペプチドVPXを有効成分として含有する上述の各種製剤は、ヒトを含む動物に摂取又は投与して、上述の、高血糖症、糖尿病(特に2型糖尿病)及び糖尿病合併症(例えば、糖尿病性の血管内皮障害や腎症、高血圧等)、血管内皮障害、血管障害等の予防、改善及び/又は治療を図るための方法に使用することができる。
また、本開示のペプチドVPX及びこれを有効成分として含有する上述の各種製剤は、上述のような高血糖症、糖尿病、血管障害、高血圧症等の予防、改善及び/又は治療のためのヒト若しくは動物用の医薬品、医薬部外品、皮膚外用剤、化粧品及び食品等の有効成分としてこれらに配合して使用可能である。
医薬品に配合する場合、経口投与剤や非経口投与剤などとすることができる。また、食品に配合する場合には、上述のジペプチジルペプチダーゼ-IVに起因する各種疾患及び/又はアンジオテンシン変換酵素に起因する各種疾患、並びに高血糖状態及び/又は高血圧症によって引き起こされる各種疾患などの予防、改善又は治療、ジペプチジルペプチダーゼ-IV阻害、血糖値上昇抑制、高血糖改善、アンジオテンシン変換酵素阻害及び血圧降下等の生理機能をコンセプトとする機能性食品、病者用食品、特定保健用食品などに応用できる。
本開示のペプチドVPX及びこれを有効成分として含有する上述の各種製剤は、上述のような、高血糖症、糖尿病、高血圧症、血管障害等の予防、改善及び/又は治療のためのヒト若しくは動物用の医薬品、医薬部外品、皮膚外用剤、化粧品及び食品等の有効成分としてこれらに配合して使用可能である。
製剤化に際しては、乳蛋白加水分解物や本開示のペプチドVPXの他に、通常製剤化に用いられている賦形剤、pH調整剤、着色剤、矯味剤等の成分を用いることができる。また、公知の又は将来的に見出されるジペプチジルペプチダーゼ-IV阻害作用及び/又はアンジオテンシン変換酵素阻害作用を有する薬、抗糖尿病薬、高血糖改善薬、血圧降下薬などを併用することも可能である。
このような食品として、液状、ペースト状、固体、粉末等の形態を問わず、錠菓、流動食、飼料(ペット用を含む)等のほか、例えば、小麦粉製品、即席食品、農産加工品、水産加工品、畜産加工品、乳・乳製品、油脂類、基礎調味料、複合調味料・食品類、冷凍食品、飲料、これら以外の市販品等が挙げられる。
例えば、前記農産加工品として、農産缶詰め、果実缶詰め、ジャム・マーマレード類、漬物、煮豆類、農産乾物類、シリアル(穀物加工品)等が挙げられる。前記水産加工品として、水産缶詰め、魚肉ハム・ソーセージ、水産練り製品、水産珍味類、つくだ煮類等が挙げられる。前記畜産加工品として、畜産缶詰め・ペースト類、畜肉ハム・ソーセージ等が挙げられる。
例えば、前記乳・乳製品として、加工乳、乳飲料、ヨーグルト類、乳酸菌飲料類、チーズ、アイスクリーム類、調製粉乳類、クリーム、その他の乳製品等が挙げられる。前記油脂類として、バター、マーガリン類、植物油等が挙げられる。
例えば、前記基礎調味料として、しょうゆ、みそ、ソース類、トマト加工調味料、みりん類、食酢類等が挙げられ、前記複合調味料・食品類として、調理ミックス、カレーの素類、たれ類、ドレッシング類、めんつゆ類、スパイス類、その他の複合調味料等が挙げられる。
例えば、前記冷凍食品として、素材冷凍食品、半調理冷凍食品、調理済冷凍食品等が挙げられる。
例えば、前記菓子類として、キャラメル、キャンディー、チューインガム、チョコレート、クッキー、ビスケット、ケーキ、パイ、スナック、クラッカー、和菓子、米菓子、豆菓子、デザート菓子、その他の菓子等が挙げられる。
例えば、前記飲料類として、炭酸飲料、天然果汁、果汁飲料、果汁入り清涼飲料、果肉飲料、果粒入り果実飲料、野菜系飲料、豆乳、豆乳飲料、コーヒー飲料、お茶飲料、粉末飲料、濃縮飲料、スポーツ飲料、栄養飲料、アルコール飲料、その他の嗜好飲料等が挙げられる。
例えば、上記以外の市販食品として、ベビーフード、ふりかけ、お茶潰けのり等が挙げられる。
本開示のペプチドVPXの投与量は、年齢、症状等により異なるが、通常、0.001~3000mg/日、好ましくは0.01~30mg/日であり、1日1回から3回に分けて投与してもよい。
<1>カゼインの酵素分解
市販のカゼイン(ニュージーランドデーリーボード製)100gに水900gを加え、よく分散させ、水酸化ナトリウムを添加して溶液のpHを7.0に調整し、カゼインを完全に溶解した。該カゼイン水溶液を85℃で10分間加熱殺菌し、50℃に温度調整し、水酸化ナトリウムを添加してpHを9.0に調整した後、パンクレアチンを2g(天野エンザイム社製)、プロテアーゼAを4g(天野エンザイム社製)それぞれ添加して、加水分解反応を開始した。カゼインの分解率が54.9%に達した時点で、80℃で6分間加熱して酵素を失活させて酵素反応を停止し、10℃に冷却した。この加水分解液を珪藻土ろ過し、濃縮後凍結乾燥し、凍結乾燥品80gを得た。
逆相HPLCで上記カゼイン加水分解物の分離を行った。このHPLC条件は下記HPLC条件1に示した。
〔HPLC条件1〕
カラム:Cadenza CD-C18
10mmI.D.×250mm (インタクト(株)製)
検出:UV 215nm
流速:3ml/分
溶離液A:0.2% FAを含む水溶液
溶離液B:0.2% FAを含むアセトニトリル溶液
溶離液Aの割合98%から、30分後に75%、40分後に50%、43分後に20%、になるようなグラジエント条件で、加水分解物を分離し、溶出液を0.75ml毎に分画した。溶出画分について、ジペプチジルペプチダーゼ-IV阻害能を測定したところリテンションタイム16.5分に溶出された画分(画分1)に強い阻害活性能が認められた。
さらに、精製するため、別条件のHPLCで精製した。このときの条件を下記HPLC条件2に示した。このとき、条件1の溶離液A、Bを、それぞれ条件2の溶離液A、Bに変更し、その他の条件は条件1と同様に行った。
〔HPLC条件2〕
カラム:Cadenza CD-C18
10mmI.D.×250mm (インタクト(株)製)
検出:UV 215nm
流速:3ml/分
溶離液A:0.1% TFAを含む水溶液
溶離液B:0.1% TFAを含むアセトニトリル溶液
上記活性ピークの画分2の化合物を、島津製作所製のプロテイン・シーケンサー(PPSQ-23A)で同定した。その結果、Val-Pro-Ala(配列番号2)という新規な構造をもつことがわかった。なお、これらアミノ酸残基はL-型であった。
更に、サーモクエスト社製質量分析計LTQにより、分子量は285.2、m/z=286.2(MH+)をプリカーサーイオンとするMS/MS分析により、図1に示す通り、m/z=169.3,187.2,197.1等のプロダクトイオンが検出された。
こうして、ジペプチジルペプチダーゼ-IV阻害能を有するペプチドの構造は、Val-Pro-Alaであることが明らかとなった
また、後述の製造例2で得られた合成ペプチドVPA(配列番号2)での50%阻止濃度は、1.9μg/mlであり、精製フラクションの値と一致した。
よって、上記<1>カゼイン酵素分解物中には、VPA(配列番号2)及びVPQ(配列番号3)がジペプチジルペプチダーゼ-IV阻害活性を持つ新規なペプチドとして含まれることが確認できた。
さらに、上記<1>カゼイン加水分解物には、ジペプチジルペプチダーゼ-IV阻害活性が認められ、その分解物中には、VPV(配列番号7)、VPY(配列番号8)、VPK(配列番号10)が含まれていたことも確認できた。なお、これらアミノ酸残基は全てL-型であった。
ペプチドシンセサイザー(Model 433A型、アプライドバイオシステムズ社)を使用し、Fmoc-Val((株)ペプチド研究所))、Fmoc-Pro((株)ペプチド研究所)、Fmoc-Ala-Wang-PEG Resin(渡辺化学工業(株))を原料に用いて、固相合成法によりトリペプチドVal-Pro-Alaを合成した。
操作はアプライドバイオシステムズ社のマニュアルに従って行った後、脱保護した。このペプチドは、上記HPLC条件1で精製した。
得られたトリペプチドは、質量分析により分子量(M)は285.2と測定され、m/z=286.2(MH+)をプリカーサーイオンとするMS/MS分析により、精製フラクションでのスペクトルと同様のスペクトルが得られた。また、VPQ(配列番号3)も同様に作成し、これは精製フラクションでのスペクトルと同様のスペクトル(質量分析による分子量(M)は342.2)が得られた。
さらに、VPM(配列番号4)、VPN(配列番号5)、VPG(配列番号6)、VPV(配列番号7)、VPY(配列番号8)、VPS(配列番号9)及びVPK(配列番号10)についても製造例2に準じて操作することで、これらペプチドを化学合成した。
表1に示す、製造例2で得た各ペプチドのジペプチジルペプチダーゼ-IV阻害活性確認試験を行い、その結果を表1に示した。
また、VPA(配列番号2)及びVPK(配列番号10)のACE阻害活性確認試験を行った結果、50%阻止濃度は、それぞれ24.8μg/ml及び132μg/mlであった。よって、このVPA及びVPKは、ジペプチジルペプチダーゼ-IV阻害作用及びアンジオテンシン変換酵素阻害作用の両方の性質を有するため、血管改善、血管内皮障害抑制及び糖尿病の予防、改善又は治療に非常に有効なものと言える。
VPAを少なくとも含む市販品のカゼイン分解物を検索したところ、CU5000(森永乳業社製)のカゼイン分解物にVPAが認められ、これらのジペプチジルペプチダーゼ-IV阻害の50%阻止濃度は、84μg/mlであった。なお、C800(森永乳業社製)についてのジペプチジルペプチダーゼ-IV阻害の50%阻止濃度は、>1000μg/mlであり、カゼイン分解物であってもジペプチジルペプチダーゼ-IV阻害活性が認められないものがあった。
ジペプチジルペプチダーゼ-IV(DPP-4)阻害の測定は、カトウらの方法「Kato, T. et al. Biochem. Med. 19, p351, 1978」に準じて行った。
具体的には、酵素(DPP-4)は Recombinant Human DPPIV/CD26 (R&D Systems, Inc.)、基質はH-Gly-Pro-AMC (Biomol GmbH) を用いて、酵素反応を行なった。
96穴マイクロプレート(nunc 137101)の各ウエルに、水又は各濃度の試験物質の水溶液または、HPLCの分画フラクションを添加し、Tris-HCl(0.25M,pH8.0)を20μl添加して全量を80μlに調製した。撹拌の後プレートを37℃のインキュベーターで約10分程度温め、DPP-4溶液10μlと、基質溶液10μlを添加し(全液量100μl)、撹拌して反応を開始した。酵素の代わりに水を添加したウエルをコントロールとした。
酵素反応の測定はマイクロプレートリーダー(SH-9000,コロナ電気(株))を用い、庫内温度を37℃に保った条件下で測定した(5分間隔、ex360nm/em460nm)。
蛍光強度の経時的な増加が直線的な期間(反応開始から30分以内)の蛍光強度の値から、下式により阻害活性を算出した陽性対象として Vildagliptin (JS Research Chemicals Trading 社)を用いた。
X:水+酵素+基質
Y:試験物質+酵素+基質
a:水+基質
b:試験物質+基質
<IC50の濃度の求め方>
試験物質の濃度を段階的に希釈し(10~2000μg/ml)、その阻害率を求めた。その結果を基に試験物質の添加濃度の対数(log10)と阻害率の間の関係式を求めた。
そしてこの関係式から酵素の阻害率が50%になる濃度を逆算することで、IC50を算出した。
アンジオテンシン変換酵素阻害(ACE阻害)の測定は、Araujoらの方法〔Araujo, M.C., et al., Biochemistry 39, 8519, 2000〕に準じて行った。
酵素(ACE)は Angiotensin Converting Enzyme, from rabbit lung (SIGMA)、基質は Abz-FRK(Dnp)-P (Enzo Life Sciences International, Inc.)を用いて、酵素反応を行なった(Araujo, M.C., et al., Biochemistry 39, 8519, 2000)。
96穴マイクロプレート(nunc 137101)の各ウエルに、水または各濃度の試験物質の水溶液または、HPLC の分画フラクションを添加し、Tris-HCl(0.25M, pH 8.0)を20μl添加して全量を80μlに調製した。撹拌の後プレートを37℃のインキュベーターで約10分程度温め、ACE溶液10μlと、基質溶液10μlを添加し(全液量100μl)、撹拌して反応を開始した。酵素の代わりに水を添加したウエルをコントロールとした。
酵素反応の測定はマイクロプレートリーダー(SH-9000, コロナ電気(株))を用い、庫内温度を37℃に保った条件下で測定した(5分間隔、ex320nm/em420nm)。
蛍光強度の経時的な増加が直線的な期間(反応開始から30分以内)の蛍光強度の値から、下式により阻害活性を算出した。
阻害率(%)=100%-[(Y-b)/(X-a)]×100%
X:水+酵素+基質
Y:試験物質+酵素+基質
a:水+基質
b:試験物質+基質
<IC50の濃度の求め方>
試験物質の濃度を段階的に希釈し(10~2000μg/ml)、その阻害率を求める。その結果を基に試験物質の添加濃度の対数(log10)と阻害率の間の関係式を求めた。そしてこの関係式から酵素の阻害率が50%になる濃度を逆算することで、IC50を算出した。
〔1〕Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕。
〔3〕前記Xは、アラニン残基、グルタミン残基、メチオニン残基、アスパラギン残基、グリシン残基、バリン残基、チロシン残基、セリン残基及びリシン残基から選ばれる前記〔1〕又は〔2〕記載のペプチド。
〔4〕前記ペプチドが、下記の(a)~(i)のいずれかのアミノ酸配列からなるペプチドから選ばれる1種又は2種以上のものである前記〔1〕~〔3〕のいずれか1項記載のペプチド。
(a)Val-Pro-Ala(配列番号2)
(b)Val-Pro-Gln(配列番号3)
(c)Val-Pro-Met(配列番号4)
(d)Val-Pro-Asn(配列番号5)
(e)Val-Pro-Gly(配列番号6)
(f)Val-Pro-Val(配列番号7)
(g)Val-Pro-Tyr(配列番号8)
(h)Val-Pro-Ser(配列番号9)
(i)Val-Pro-Lys(配列番号10)
生理活性の点で好適には、VPA(配列番号2)、VPQ(配列番号3)、VPN(配列番号5)、VPG(配列番号6)、VPV(配列番号7)、VPY(配列番号8)、VPS(配列番号9)、VPK(配列番号10)である。
ジペプチジルペプチダーゼ-IV阻害活性の点で、VPA(配列番号2)、VPQ(配列番号3)、VPV(配列番号7)であるのが好適である。
アンジオテンシン変換酵素阻害活性の点で、VPA(配列番号2)、VPK(配列番号10)であるのが好適である。
ジペプチジルペプチダーゼ-IV阻害剤、高血糖改善剤、血糖値上昇抑制剤、抗糖尿病剤、血管内皮障害抑制剤、血管改善剤、アンジオテンシン変換酵素阻害剤、血圧降下剤又は抗高血圧症剤。
〔6〕ジペプチジルペプチダーゼ-IV阻害剤、高血糖改善剤、血糖値上昇抑制剤、抗糖尿病剤、血管内皮障害抑制剤、血管改善剤、アンジオテンシン変換酵素阻害剤、血圧降下剤又は抗高血圧症剤の製造のための、
Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は前記〔2〕~〔4〕のいずれか1項記載のペプチドの使用。
〔7〕ジペプチジルペプチダーゼ-IV阻害用食品、高血糖改善剤、血糖値上昇抑制用食品、抗糖尿病用食品、血管内皮障害抑制用食品、血管改善用食品、アンジオテンシン変換酵素阻害用食品、血圧降下用食品の製造のための、
Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は前記〔2〕~〔4〕のいずれか1項記載のペプチドの使用。
ジペプチジルペプチダーゼ-IV阻害剤、高血糖改善剤、血糖値上昇抑制剤、抗糖尿病剤、血管内皮障害抑制剤、血管改善剤、アンジオテンシン変換酵素阻害剤、血圧降下剤又は抗高血圧症剤への使用。
〔9〕Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は前記〔2〕~〔4〕のいずれか1項記載のペプチドの、
ジペプチジルペプチダーゼ-IV阻害用食品、血糖低下用食品、抗糖尿病用食品、血管内皮障害抑制用食品又は血管改善用食品への使用。
〔10〕ジペプチジルペプチダーゼ-IVに起因する疾患、高血糖状態に起因する疾患、糖尿病、血管内皮障害若しくは血管障害に起因する疾患、アンジオテンシン変換酵素に起因する疾患、高血圧状態に起因する疾患の、予防、改善又は治療のための、
Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は前記〔2〕~〔4〕のいずれか1項記載のペプチド。
〔11〕Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は前記〔2〕~〔4〕のいずれか1項記載のペプチドを有効成分として、
ジペプチジルペプチダーゼ-IVに起因する疾患、高血糖状態に起因する疾患、糖尿病、血管内皮障害若しくは血管障害に起因する疾患、アンジオテンシン変換酵素に起因する疾患、高血圧状態に起因する疾患の、予防、改善又は治療方法。
〔12〕ジペプチジルペプチダーゼ-IVに起因する疾患、高血糖状態に起因する疾患、糖尿病、血管内皮障害若しくは血管障害に起因する疾患、アンジオテンシン変換酵素に起因する疾患、高血圧状態に起因する疾患の、予防、改善又は治療における使用のための、
Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は前記〔2〕~〔4〕のいずれか1項記載のペプチド。
〔13〕ジペプチジルペプチダーゼ-IVに起因する疾患、高血糖状態に起因する疾患、糖尿病、血管内皮障害若しくは血管障害に起因する疾患、アンジオテンシン変換酵素に起因する疾患、高血圧状態に起因する疾患の、予防、改善又は治療のための、
Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は前記〔2〕~〔4〕のいずれか1項記載のペプチドの使用。
〔15〕前記アンジオテンシン変換酵素に起因する疾患及び/又は症状が、高血圧症、心血管疾患から選ばれるものであるのが好適である。
〔16〕カゼインを加水分解して得られるVal-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は前記〔2〕~〔4〕のいずれか1項記載のペプチド及びその製造方法。
〔17〕カゼインを以下の工程にて分離精製して得られる、Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕又は前記〔2〕~〔4〕のいずれか1項記載のペプチド及びその製造方法。
(a)加水分解酵素(好適にはエンドペプチダーゼ)にて行うこと。好適には10~85℃、0.1~48時間の条件下にて行う。
(b)その加水分解分解物を、クロマトグラフィーにて分離精製すること。好適にはイオン交換クロマトグラフィー、逆相クロマトグラフィー、分配クロマトグラフィー等から選ばれる1種又は2種のものを使用。
Claims (18)
- Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕。
- 前記Xは、塩基性アミノ酸残基、脂肪族中性アミノ酸残基、ヒドロキシ基を有する中性アミノ酸残基、アミド基を有する中性アミノ酸残基及び芳香族を有する中性アミノ酸残基から選ばれるものである請求項1記載のペプチド。
- 前記Xが、アラニン残基、グルタミン残基、メチオニン残基、アスパラギン残基、グリシン残基、バリン残基、チロシン残基、セリン残基及びリシン残基から選ばれるものである請求項1又は2記載のペプチド。
- 前記ペプチドが、下記の(a)~(i)のいずれかのアミノ酸配列からなるペプチドから選ばれるものである請求項1~3の何れか1項記載のペプチド。
(a)Val-Pro-Ala(配列番号2)
(b)Val-Pro-Gln(配列番号3)
(c)Val-Pro-Met(配列番号4)
(d)Val-Pro-Asn(配列番号5)
(e)Val-Pro-Gly(配列番号6)
(f)Val-Pro-Val(配列番号7)
(g)Val-Pro-Tyr(配列番号8)
(h)Val-Pro-Ser(配列番号9)
(i)Val-Pro-Lys(配列番号10) - Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕を有効成分として含有するジペプチジルペプチダーゼ-IV阻害剤。
- 前記ペプチドが、請求項2~4の何れか1項記載のペプチドである請求項5記載のジペプチジルペプチダーゼ-IV阻害剤。
- Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕を有効成分として含有する血糖値上昇抑制剤。
- 前記ペプチドが、請求項2~4の何れか1項記載のペプチドである請求項7記載の血糖値上昇抑制剤。
- Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕を有効成分として含有する血管内皮障害抑制剤。
- 前記ペプチドが、請求項2~4の何れか1項記載のペプチドである請求項9記載の血管内皮障害抑制剤。
- Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕を有効成分として含有するアンジオテンシン変換酵素阻害剤。
- 前記ペプチドが、請求項2~4の何れか1項記載のペプチドである請求項11記載のアンジオテンシン変換酵素阻害剤。
- ジペプチジルペプチダーゼ-IV阻害剤、血糖値上昇抑制剤、血管内皮障害抑制剤、又はアンジオテンシン変換酵素阻害剤の製造のための、Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕の使用。
- ジペプチジルペプチダーゼ-IV阻害用食品、血糖値上昇抑制用食品、血管内皮障害抑制用食品、アンジオテンシン変換酵素阻害用食品の製造のための、Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕の使用。
- Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕の、ジペプチジルペプチダーゼ-IV阻害剤、血糖値上昇抑制剤、血管内皮障害抑制剤、アンジオテンシン変換酵素阻害剤への使用。
- Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕の、ジペプチジルペプチダーゼ-IV阻害用食品、血糖値上昇抑制用食品、血管内皮障害抑制用食品、アンジオテンシン変換酵素阻害用食品への使用。
- ジペプチジルペプチダーゼ-IVに起因する疾患、高血糖状態に起因する疾患、糖尿病、血管内皮障害若しくは血管障害に起因する疾患、アンジオテンシン変換酵素に起因する疾患、高血圧状態に起因する疾患の、予防、改善又は治療における使用のための、Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は請求項2~4のいずれか1項記載のペプチド。
- Val-Pro-Xからなるペプチド〔式中、Xはアミノ酸残基(L-プロリン残基を除く)を示す〕、又は請求項2~4のいずれか1項記載のペプチドを有効成分として、ジペプチジルペプチダーゼ-IVに起因する疾患、高血糖状態に起因する疾患、糖尿病、血管内皮障害若しくは血管障害に起因する疾患、アンジオテンシン変換酵素に起因する疾患、高血圧状態に起因する疾患の、予防、改善又は治療方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380013217.XA CN104159912B (zh) | 2012-03-09 | 2013-02-21 | 二肽基肽酶iv 抑制剂 |
MX2014008420A MX2014008420A (es) | 2012-03-09 | 2013-02-21 | Inhibidor de dipeptidil peptidasa-iv. |
EP13758259.9A EP2824110A4 (en) | 2012-03-09 | 2013-02-21 | DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
JP2014503756A JP5832049B2 (ja) | 2012-03-09 | 2013-02-21 | ジペプチジルペプチダーゼ−iv阻害剤 |
US14/383,618 US9617300B2 (en) | 2012-03-09 | 2013-02-21 | Dipeptidyl peptidase-IV inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012053855 | 2012-03-09 | ||
JP2012-053855 | 2012-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013133031A1 true WO2013133031A1 (ja) | 2013-09-12 |
Family
ID=49116514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/054291 WO2013133031A1 (ja) | 2012-03-09 | 2013-02-21 | ジペプチジルペプチダーゼ-iv阻害剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9617300B2 (ja) |
EP (1) | EP2824110A4 (ja) |
JP (1) | JP5832049B2 (ja) |
CN (2) | CN104159912B (ja) |
MX (1) | MX2014008420A (ja) |
WO (1) | WO2013133031A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018537462A (ja) * | 2015-12-16 | 2018-12-20 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | 新規な使用 |
JP2020000014A (ja) * | 2018-06-25 | 2020-01-09 | サンスター株式会社 | トリペプチド含有組成物 |
WO2024038888A1 (ja) * | 2022-08-19 | 2024-02-22 | 森永乳業株式会社 | 組成物 |
JP7453665B2 (ja) | 2019-01-29 | 2024-03-21 | 国立大学法人鳥取大学 | ジペプチジルペプチダーゼiv阻害活性が高い発酵乳およびその製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106317172A (zh) * | 2015-06-23 | 2017-01-11 | 首都医科大学 | Pro-Ser,其合成,活性和应用 |
CN107337710A (zh) * | 2017-07-26 | 2017-11-10 | 盐城卫生职业技术学院 | 一种抗高血压活性肽The‑The‑Pro及应用和药物组合物 |
CN113801192B (zh) * | 2021-08-31 | 2023-06-20 | 华南理工大学 | 一种抑制二肽基肽酶iv的四肽及其应用 |
CN114349818A (zh) * | 2021-12-31 | 2022-04-15 | 华南理工大学 | 一类具有双靶点降糖功能的三肽及其应用 |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0640944A (ja) | 1992-07-23 | 1994-02-15 | Calpis Food Ind Co Ltd:The | アンジオテンシン変換酵素阻害剤及びその製造法 |
JPH07101982A (ja) | 1993-10-06 | 1995-04-18 | Nippon Synthetic Chem Ind Co Ltd:The | 新規ペプチド、それを製造する方法及び用途 |
JPH0899994A (ja) * | 1994-08-02 | 1996-04-16 | Calpis Food Ind Co Ltd:The | ペプチド及び血圧降下剤及びその製造法 |
JPH09227591A (ja) * | 1996-02-12 | 1997-09-02 | Hoechst Ag | オリゴペプチドアルデヒドの製造方法 |
WO1999048910A1 (en) * | 1998-03-26 | 1999-09-30 | University Of Dundee | Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease |
JP2001136995A (ja) | 1999-11-11 | 2001-05-22 | Calpis Co Ltd | トリペプチドの製造方法 |
WO2003031574A2 (en) * | 2001-10-05 | 2003-04-17 | North Shore - Long Island Jewish Research Institute | Elastase inhibitors |
WO2003044044A1 (fr) | 2001-11-21 | 2003-05-30 | Morinaga Milk Industry Co., Ltd. | Nouveau peptide exerçant un effet inhibiteur d'angiotensine convertase |
CN1660888A (zh) * | 2004-12-29 | 2005-08-31 | 山东大学 | 中国毛虾蛋白降压肽及其制备方法与应用 |
WO2006068480A2 (en) | 2004-12-23 | 2006-06-29 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use |
WO2006108211A1 (en) * | 2005-02-25 | 2006-10-19 | The Murdoch Childrens Research Institute | Fragments of von willebrand factor a-related protein |
JP2007039424A (ja) | 2005-07-01 | 2007-02-15 | Snow Brand Milk Prod Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
US20080075904A1 (en) | 2005-02-04 | 2008-03-27 | Daikin Industries, Ltd. | Crosslinkable Composition and Laminated Article Made of Same |
JP2008527011A (ja) | 2005-01-19 | 2008-07-24 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療用又は予防用のジペプチジルペプチダーゼ−iv阻害剤としての二環系ピリミジン |
JP2008280291A (ja) | 2007-05-10 | 2008-11-20 | Uha Mikakuto Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
WO2010072327A2 (de) * | 2008-12-16 | 2010-07-01 | Kamamed Gmbh | Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch |
WO2010077988A2 (en) * | 2008-12-16 | 2010-07-08 | Jerzy Alexander Georgiades | Role of proline rich peptides in cellular communication mechanisms and treatment of diseases |
WO2011007612A1 (ja) * | 2009-07-13 | 2011-01-20 | 不二製油株式会社 | 経口性抗炎症剤及び経口性抗炎症ペプチド |
JP2011144167A (ja) | 2009-12-18 | 2011-07-28 | Meiji Co Ltd | 血糖値降下剤及び血糖値降下飲食品組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
WO2003002593A2 (en) * | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
JP4840837B2 (ja) * | 2001-09-28 | 2011-12-21 | 日本たばこ産業株式会社 | 旨味を有する新規ペプチド、及びそれを旨味成分とする調味料 |
EP1298210A1 (en) | 2001-10-01 | 2003-04-02 | Societe Des Produits Nestle S.A. | Cocoa flavour precursor peptides |
WO2009052489A2 (en) | 2007-10-19 | 2009-04-23 | Alba Therapeutics Corporation | Novel inhibitors of mammalian tight junction opening |
-
2013
- 2013-02-21 MX MX2014008420A patent/MX2014008420A/es unknown
- 2013-02-21 JP JP2014503756A patent/JP5832049B2/ja active Active
- 2013-02-21 CN CN201380013217.XA patent/CN104159912B/zh active Active
- 2013-02-21 CN CN201610269709.0A patent/CN105833256A/zh active Pending
- 2013-02-21 WO PCT/JP2013/054291 patent/WO2013133031A1/ja active Application Filing
- 2013-02-21 EP EP13758259.9A patent/EP2824110A4/en not_active Withdrawn
- 2013-02-21 US US14/383,618 patent/US9617300B2/en active Active
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0640944A (ja) | 1992-07-23 | 1994-02-15 | Calpis Food Ind Co Ltd:The | アンジオテンシン変換酵素阻害剤及びその製造法 |
JPH07101982A (ja) | 1993-10-06 | 1995-04-18 | Nippon Synthetic Chem Ind Co Ltd:The | 新規ペプチド、それを製造する方法及び用途 |
JPH0899994A (ja) * | 1994-08-02 | 1996-04-16 | Calpis Food Ind Co Ltd:The | ペプチド及び血圧降下剤及びその製造法 |
JPH09227591A (ja) * | 1996-02-12 | 1997-09-02 | Hoechst Ag | オリゴペプチドアルデヒドの製造方法 |
WO1999048910A1 (en) * | 1998-03-26 | 1999-09-30 | University Of Dundee | Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease |
JP2001136995A (ja) | 1999-11-11 | 2001-05-22 | Calpis Co Ltd | トリペプチドの製造方法 |
WO2003031574A2 (en) * | 2001-10-05 | 2003-04-17 | North Shore - Long Island Jewish Research Institute | Elastase inhibitors |
WO2003044044A1 (fr) | 2001-11-21 | 2003-05-30 | Morinaga Milk Industry Co., Ltd. | Nouveau peptide exerçant un effet inhibiteur d'angiotensine convertase |
WO2006068480A2 (en) | 2004-12-23 | 2006-06-29 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use |
CN1660888A (zh) * | 2004-12-29 | 2005-08-31 | 山东大学 | 中国毛虾蛋白降压肽及其制备方法与应用 |
JP2008527011A (ja) | 2005-01-19 | 2008-07-24 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療用又は予防用のジペプチジルペプチダーゼ−iv阻害剤としての二環系ピリミジン |
US20080075904A1 (en) | 2005-02-04 | 2008-03-27 | Daikin Industries, Ltd. | Crosslinkable Composition and Laminated Article Made of Same |
WO2006108211A1 (en) * | 2005-02-25 | 2006-10-19 | The Murdoch Childrens Research Institute | Fragments of von willebrand factor a-related protein |
JP2007039424A (ja) | 2005-07-01 | 2007-02-15 | Snow Brand Milk Prod Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
JP2008280291A (ja) | 2007-05-10 | 2008-11-20 | Uha Mikakuto Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
WO2010072327A2 (de) * | 2008-12-16 | 2010-07-01 | Kamamed Gmbh | Pharmazeutische zusammensetzung auf basis von peptid aus kamelmilch |
WO2010077988A2 (en) * | 2008-12-16 | 2010-07-08 | Jerzy Alexander Georgiades | Role of proline rich peptides in cellular communication mechanisms and treatment of diseases |
WO2011007612A1 (ja) * | 2009-07-13 | 2011-01-20 | 不二製油株式会社 | 経口性抗炎症剤及び経口性抗炎症ペプチド |
JP2011144167A (ja) | 2009-12-18 | 2011-07-28 | Meiji Co Ltd | 血糖値降下剤及び血糖値降下飲食品組成物 |
Non-Patent Citations (12)
Title |
---|
"SHOKUHINBUNSEKIHO", 1984, KORIN PUBLISHING CO., LTD., article "Food analysis method", pages: 102 |
ARAUJO, M.C. ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 8519 |
CARDIOVASCULAR DIABETOLOGY, vol. 10, no. 85, 2011, Retrieved from the Internet <URL:http V/www. cardiab. com/conte nt/10/1/85> |
DIABETES CARE., vol. 34, no. 9, 2011, pages 2072 - 7 |
ENDOCRINE JOURNAL, vol. 58, no. 1, 2011, pages 69 - 73 |
J AM COLL CARDIOL., vol. 59, no. 3, 2012, pages 265 - 76 |
KATO, T. ET AL., BIOCHEM. MED., vol. 19, 1978, pages 351 |
MINERVINI F. ET AL.: "Angiotensin I-converting- enzyme-inhibitory and antibacterial peptides from Lactobacillus helveticus PR4 proteinase- hydrolyzed caseins of milk from six species.", APPL. ENVIRON. MICROBIOL., vol. 69, no. 9, 2003, pages 5297 - 5305, XP002991856 * |
MITSUDA ET AL.: "SHOKUHINKOGAKU JIKKENSHO", 1970, YOKENDO CO., LTD., pages: 547 |
RYAN K. ET AL.: "Construction of sequence- selective peptide receptors from conformationally restricted eta- and theta- amino acids.", BIOORG. MED. CHEM. LETT., vol. 9, no. 18, 1999, pages 2673 - 2678, XP004179950 * |
See also references of EP2824110A4 |
VAN PLATERINK C.J. ET AL.: "Application of at- line two-dimensional liquid chromatography-mass spectrometry for identification of small hydrophilic angiotensin I-inhibiting peptides in milk hydrolysates.", ANAL. BIOANAL. CHEM., vol. 391, no. 1, 2008, pages 299 - 307, XP019621367 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018537462A (ja) * | 2015-12-16 | 2018-12-20 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | 新規な使用 |
JP7115310B2 (ja) | 2015-12-16 | 2022-08-09 | ディーエスエム アイピー アセッツ ビー.ブイ. | 新規な使用 |
JP2020000014A (ja) * | 2018-06-25 | 2020-01-09 | サンスター株式会社 | トリペプチド含有組成物 |
JP7068942B2 (ja) | 2018-06-25 | 2022-05-17 | サンスター株式会社 | トリペプチド含有組成物 |
JP7453665B2 (ja) | 2019-01-29 | 2024-03-21 | 国立大学法人鳥取大学 | ジペプチジルペプチダーゼiv阻害活性が高い発酵乳およびその製造方法 |
WO2024038888A1 (ja) * | 2022-08-19 | 2024-02-22 | 森永乳業株式会社 | 組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN105833256A (zh) | 2016-08-10 |
CN104159912B (zh) | 2016-11-09 |
CN104159912A (zh) | 2014-11-19 |
EP2824110A1 (en) | 2015-01-14 |
JP5832049B2 (ja) | 2015-12-16 |
EP2824110A4 (en) | 2015-12-30 |
US9617300B2 (en) | 2017-04-11 |
MX2014008420A (es) | 2015-03-03 |
JPWO2013133031A1 (ja) | 2015-07-30 |
US20150232510A1 (en) | 2015-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5832049B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
JP6189994B2 (ja) | ジペプチジルペプチダーゼ−iv阻害用飲食品組成物 | |
AU2002366037B2 (en) | Novel peptide having angiotensin convertase inhibitory effect | |
JP6344796B2 (ja) | 高齢者用アルツハイマー型認知症改善剤 | |
JP2015084694A (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
JP5976004B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
JP5877560B2 (ja) | ジペプチジルペプチダーゼ−iv阻害剤 | |
CA2681593A1 (en) | Preventive or therapeutic composition for liver disease | |
WO2005061529A1 (ja) | アンジオテンシン変換酵素阻害ペプチド | |
JP6345630B2 (ja) | 新規ペプチド及びその用途 | |
WO2022186290A1 (ja) | ジペプチジルペプチダーゼ-iv阻害剤 | |
WO2014030977A1 (ko) | 안지오텐신-i 전환 효소 저해능을 나타내는 펩타이드를 유효성분으로 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물 | |
WO2024038888A1 (ja) | 組成物 | |
JP6589011B2 (ja) | 脳機能障害改善用経口組成物 | |
JP2017048124A (ja) | アミノペプチダーゼa阻害剤 | |
JP2023110462A (ja) | ジペプチジルペプチダーゼ-iv阻害活性を有するペプチド及びその利用 | |
JP5430803B2 (ja) | ペプチドおよびアンジオテンシン変換酵素阻害剤 | |
JP2021100412A (ja) | カゼイン酵素処理物及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13758259 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014503756 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/008420 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14383618 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2013758259 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013758259 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201304861 Country of ref document: ID Ref document number: IDP00201406117 Country of ref document: ID |